WHO Director General Tedros Adhanom Ghebreyesus says the world’s biggest ultra-processed food corporations are obstructing the adoption of public health measures aimed at tackling the obesity crisis. In an exclusive claim reported by The Guardian, he links that obstruction to lawsuits filed against governments that try to promote healthier diets.

Tedros also argues these legal battles are costing countries “billions of dollars,” not only in healthcare outcomes but in healthcare and legal costs as well. The thrust is clear: the obesity fight is not only about nutrition science and public campaigns. It is also about who can enforce policy quickly, and who can slow it down through litigation.

To understand why this claim has outsized implications, zoom out to how obesity policy usually moves. Governments set rules or incentives intended to shift population-level behavior, often through restrictions, labeling changes, procurement standards, taxes, or other measures meant to steer people away from ultra-processed foods. Those initiatives rarely land without opposition, because they can re-price consumer demand, reshape product portfolios, and pressure marketing budgets.

What Tedros is alleging adds a specific layer: the obstruction may happen in court, not only in public debate. The WHO director general accused global food companies of hindering the adoption of “vital public health measures,” and The Guardian frames the accusation as following an investigation by the newspaper and others. If that framing is accurate, then the policy timeline becomes hostage to legal strategy, not just political negotiation.

There is also a money story underneath the words “billions.” Public budgets are typically strained even before a dispute begins. If obesity-related programs are forced to pause, redraw, or defend themselves repeatedly, healthcare spending can rise while legal spend accumulates. The second-order effect is that governments may become more cautious, choosing the “least litigated” options rather than the “most effective” ones. In practice, that can compress a country’s ability to learn and adjust, because delayed implementation means delayed results.

This is where incentives turn sharp for executives, boards, and regulators. Ultra-processed food companies operate in markets where brand and distribution matter, and where regulatory changes can hit revenue and margins. Litigation can be a way to buy time. Time can then be used for settlements, policy rewrites, or product reformulations that blunt the impact of the original policy. Even if companies do not win outright, the mere cost and duration of defending measures can reduce the political appetite to keep pushing.

On the other side, regulators and public health agencies face a coordination challenge. Health ministries, finance ministries, and legal departments often work on different rhythms. When lawsuits mount, leadership may spend energy on procedural defense instead of program expansion. Meanwhile, the public expects action on obesity, which is both a chronic health issue and a political flashpoint. Tedros’s statement, as reported, suggests corporations are treating obesity policy as an adversarial process that can be slowed through the legal system.

There is also reputational dynamics. When the WHO director general publicly accuses corporations of obstructing policy adoption, it elevates the conflict from a technical dispute to a legitimacy question. For boards, that matters because reputational damage can compound shareholder risk. For governments, it matters because it can reshape how stakeholders perceive the urgency of legal reforms, regulatory guardrails, and the resilience of public health decision-making.

For decision-makers in similar roles, the strategic stake is that obesity policy may be influenced by forces outside the normal policy toolbox. The WHO accusation implies that lawsuits can function like a second regulator, setting the pace and scope of what countries attempt. The consequence for executives, investors, and public officials is a world where health strategies must be built with litigation risk in mind from day one, not as an afterthought once a policy is announced. When “healthcare and legal costs” are in play, speed becomes an economic variable, not just a public policy preference.